StrixNB(TM) Powder Formulation Approved by Health Canada's LRVHP Program
26 Mars 2014 - 3:30PM
Marketwired
StrixNB(TM) Powder Formulation Approved by Health Canada's LRVHP
Program
StrixNB Oral Care Powder is the third product in a portfolio of
products that the Company is developing for the companion animal
oral care market.
WINNIPEG, MANITOBA--(Marketwired - Mar 26, 2014) - Kane Biotech
Inc. (TSX-VENTURE:KNE), a biotechnology company engaged in the
development and commercialization of products that prevent and
remove microbial biofilms is pleased to announce StrixNB Water
Additive is now available in a powder formulation. The Company has
received Notification Number "NN.BQ16" from the Interim
Notification Program for Low Risk Veterinary Health Products
(LRVHP) for the new StrixNB oral care application in Canada. With
the issuance of this notification number, the Company has cleared
the final requirements for StrixNB Oral Care Powder to enter the
companion animal market in Canada.
Health Canada in cooperation with the Canadian Animal Health
Institute has developed an interim notification program for
low-risk veterinary health products used in cats, dogs, and horses.
The new StrixNB Oral Care Powder will be available in a 300g
container ideal for dog breeders and multi-pet households in
addition to a single serving sachet ideal for pet owners on the
go.
Kane Biotech is developing a number of new products for the
animal health sector in order to create a portfolio of products.
The Company's antibiofilm/antimicrobial oral care and wound care
technologies can be used for a number of applications and the
company is working towards developing a broad product offering to
meet the needs of pet owners around the world.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the
development and commercialization of products to prevent and remove
biofilms. Biofilms are a major cause of a number of serious medical
problems including chronic infections and medical device related
infections. They develop on surfaces such as catheters, prosthetic
implants, teeth, lungs and the urogenital tract. Biofilms are
pervasive, costly to deal with and are involved in approximately
80% of all human bacterial infections. The healing of chronic
wounds alone costs the United States health care system $20 Billion
per year.
Kane Biotech uses patent protected technologies based on
molecular mechanisms of biofilm formation/dispersal and methods for
finding compounds that inhibit or disrupt biofilms. The Company has
evidence that these technologies have potential to significantly
improve the ability to prevent and/or destroy biofilms in several
medical and industrial applications.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release
constitute forward-looking information within the meaning of
applicable Canadian provincial securities legislation
(collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, including, without limitation, our anticipated future
operating results, and can, in some cases, be identified by the use
of words such as "believe", "anticipate", "expect", "intend",
"plan", "will", "may" and other similar expressions. In addition,
any statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements.
These statements reflect management's current beliefs and
are based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
Kane's early stage of development, lack of product revenues and
history of operating losses, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters,
management of growth, partnerships for development and
commercialization of technology, effects of insurers' willingness
to pay for products, system failures, dependence on key personnel,
foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed
from time to time in Kane's filings with Canadian securities
regulatory authorities, as well as Kane's ability to anticipate and
manage the risks associated with the foregoing. Kane cautions that
the foregoing list of important factors that may affect future
results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.
These risks and uncertainties should be considered carefully
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Kane cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update
or revise any forward-looking statement.
StrixNB™, DispersinB® and Aledex® are registered trademarks
of Kane Biotech Inc. All Rights Reserved 2014.
Kane Biotech Inc.Gord FroehlichPresident &
CEO204-477-7592204-474-7552ir@kanebiotech.comwww.kanebiotech.com
Kane Biotech (TSXV:KNE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Kane Biotech (TSXV:KNE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024